Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia

Inclusion Criteria: * Patients with documented/confirmed new onset non-m3 acute myeloid leukemia, according to WHO 2017 will be eligible for this study. * Hematological illness has to be graded intermediate or high risk according ELN criteria * Patients ≥ 18 years old and ≤ 65 years old * ECOG performance status ≤ 2. * Patients with a life expectancy \>12 weeks * Patients may have AML which has arisen from prior therapies or other antecedent disorder * Adequate hepatic function * Adequate pancreatic function * Adequate renal function assessed by: Serum creatinine within reference laboratory ranges or creatinine clearance (by Cockcroft Gault formula, see Appendix 2) ≥ 50 mL/min for patients in whom, in the Investigator's judgment, serum creatinine level may not adequately reflect renal function. * All non-hematological adverse events must have resolved to NCI-CTCAE Grade ≤ 2 prior to starting therapy. * Patients must be considered by Investigator suitable to receive combination chemotherapy. * Combination chemotherapy has not to be considered toxic without expectation of any benefit for the patient * For females of childbearing potential, a negative pregnancy test must be documented within 72 hours prior to the first study drug administration. * All patients must be willing to use effective methods of contraception, during the treatment period and for 100 days after the last dose of Venetoclax. Female patients must be postmenopausal (≥ 1 year of amenorrhea), surgically steril…